AbbVie Inc. (ABBV)
2 Urgent Sells And 2 No Brainer Dividend Buys
One thing I've learned is the pendulum always swings. It is in our best approach to sell high and buy low. This has worked well for us, as our returns suggest.
Here's Why AbbVie (ABBV) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Here's What Will Drive AbbVie's Top-line Growth in 2026
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
AbbVie's Prognosis: The February Dip Looks Like a Buy Signal
When the price of a high-quality stock such as AbbVie NYSE: ABBV declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to buy.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
AbbVie: The Market Is Getting It Wrong
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operating margin expanded 360 bps, demonstrating improved efficiency. Forward guidance for FY2026 EPS of $14.37-$14.57 implies 13% growth, exceeding analyst expectations by $0.25 per share.
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded via ImmunoGen and Cerevel acquisitions, supporting robust growth beyond immunology. Sales and EPS growth through 2030 are forecast to outpace most peers, with a projected 6.6% sales CAGR and 7.7% EPS CAGR.
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise
AbbVie Inc. retains a Strong Buy rating, driven by a positive earnings surprise in Q4 2025, notably due to HUMIRA outperformance. Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in its immunology and neuroscience portfolios, supporting continued optimism. The company's ability to exceed expectations amid headwinds underscores management's effective execution and portfolio diversification.
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience divisions are thriving, with Skyrizi and Rinvoq driving robust growth, yet competition and market saturation present future risks. Management projects high single-digit revenue CAGR through the decade, but detailed 2026 guidance limits upside surprise and leaves little room for error.
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth.
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
